Video Experimental Relacionado
Updated: Aug 7, 2026
09:37
A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
Published on: July 14, 2016
Polimorfismo del ADN adyacente al gen de la apoproteína humana A-1: relación con la hipertrigliceridemia
Lancet (London, England)
|February 26, 1983
Resumen
Un polimorfismo de ADN cerca del gen humano de la apoproteína-A-1 es más común en pacientes con hipertrigliceridemia. Esta variante genética puede indicar una predisposición a niveles altos de triglicéridos.
Área de la Ciencia:
- Genética La genética.
- Biología Molecular Biología Molecular
- La bioquímica es la bioquímica.
Sus antecedentes:
- La apolipoproteína A-1 (ApoA-1) juega un papel crucial en el metabolismo de los lípidos.
- Las variaciones genéticas en la región del gen de la apolipoproteína A-1 pueden influir en los perfiles lipídicos.
- La hipertrigliceridemia es un factor de riesgo significativo para las enfermedades cardiovasculares.
Objetivo del estudio:
- Investigar la asociación entre un polimorfismo específico del ADN en la región 3'-flanqueante del gen humano de la apoproteína-A-1 y la hipertrigliceridemia.
- Para determinar la frecuencia de este polimorfismo en individuos sanos y en pacientes con hipertrigliceridemia.
Principales métodos:
- Se usó la secuenciación del ADN para identificar y genotipar el polimorfismo.
- Se calcularon las frecuencias de alelos y genotipos y se compararon entre los grupos de pacientes y de control.
Principales resultados:
- Se identificó un polimorfismo de ADN en la región 3'-flanqueante del gen humano de la apoproteína-A-1.
- La frecuencia del estado heterocigótico fue de aproximadamente 0,05 en controles sanos (n=73).
- En sujetos con hipertrigliceridemia (n=35), la frecuencia del sitio polimórfico fue de 0,34, con 2 individuos homocigotos.
Conclusiones:
- La mayor frecuencia observada del alelo mutante en pacientes con hipertrigliceridemia sugiere un posible vínculo genético.
- Este polimorfismo puede servir como un marcador de anomalías en el gen de la apoproteína-A-1, impactando la expresión o estructura de ApoA-1.
- Estas alteraciones genéticas podrían predisponer a las personas a la hipertrigliceridemia.
Videos de Conceptos Relacionados
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...